The purpose of this study is to evaluate the efficacy and safety of GPED (gemcitabine, pegaspargase, etoposide, and dexamethasone) regimen in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
1000mg/㎡,d1,4 ivdrip
2500IU/㎡, maximum dose less than 3750IU
100mg/㎡,d1-3 ivdrip
Beijing Tongren Hospital
Beijing, China
RECRUITINGoverall response rate
evaluated by PET-CT and MRI, according to Lugano 2014 criteria
Time frame: 24 weeks ±7 days
complete response rate
evaluated by PET-CT and MRI, according to Lugano 2014 criteria
Time frame: 24 weeks ±7 days
1-year progression free survival rate
time from date of enrollment to date of disease progression, death of any reason, whichever comes first
Time frame: up to 1year after enrollment
1-year overall survival rate
time from date of enrollment to date death of any reason
Time frame: up to 1year after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
20mg/d d1-4 ivdrip